Teppei Okamoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Teppei Okamoto has a total of 257 co-authors. Here are the top co-authors by number of shared publications:
- Shingo Hatakeyama
Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan
46 shared publications Chikara Ohyama
Department of Advanced Transplant and Regenerative Medicine Hirosaki University Graduate School of Medicine Hirosaki Japan
28 shared publications- Chikara Ohyama
Department of Advanced Transplant and Regenerative Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan
18 shared publications Hayato Yamamoto
Department of Urology Hirosaki University Graduate School of Medicine Hirosaki Japan
17 shared publications- Naoki Fujita
Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan
16 shared publications - Hayato Yamamoto
Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan
14 shared publications
Latest Publications
- Open Access
- 6 November 2026
- Published by Springer Nature in BMC Cancer
Discordance between G8 and functional competence and their associations with quality of life in urological cancers
- 6 November 2026
- Published by Springer Nature in BMC Cancer
Open AccessDiscordance between G8 and functional competence and their associations with quality of life in urological cancers
- 25 September 2026
- Published by Springer Nature in World Journal of Urology
- Vol. 44 (1) , 698
Association of time to upfront treatment initiation with outcomes in metastatic hormone-sensitive prostate cancer: a 4-month landmark analysis
- 25 September 2026
- Published by Springer Nature in World Journal of Urology
- Vol. 44 (1) , 698
Association of time to upfront treatment initiation with outcomes in metastatic hormone-sensitive prostate cancer: a 4-month landmark analysis
- 14 September 2026
- Published by Wiley in International Journal of Urology
- Vol. 33 (9) , e70636
Treatment Patterns and Outcomes After Recurrence Following Adjuvant Nivolumab for Urothelial Carcinoma: An AGEHA Real‐World Study
Objectives: To describe post‐recurrence treatment patterns and outcomes after adjuvant nivolumab for urothelial carcinoma in real‐world practice. Methods: We retrospectively analyzed patients with urothelial carcinoma who underwent radical cystectomy or nephroureterectomy followed by adjuvant nivolumab in the multicenter AGEHA database. Among 141 patients, 40 developed recurrence, excluding non‐muscle‐invasive bladder recurrence. First‐line post‐recurrence treatment was categorized as enfortumab vedotin plus pembrolizumab (EVP), enfortumab vedotin (EV), non‐EV regimens, or no systemic therapy. Overall survival (OS) was measured from recurrence and progression‐free survival (PFS) from initiation of first‐line post‐recurrence therapy. Results: Of 141 patients treated with adjuvant nivolumab, 40 (28%) developed recurrence. First‐line post‐recurrence treatment was EVP in 10 patients, EV in 15, non‐EV regimens in 12, and no systemic therapy in 3. Median time from surgery and nivolumab initiation to recurrence was 5.9 and 4.2 months, respectively. Median OS from recurrence was 27.1, 26.0, and 23.4 months in the EVP, EV, and non‐EV groups, respectively, while median PFS from initiation of first‐line post‐recurrence therapy was 12.9, 7.6, and 8.7 months. Baseline characteristics differed across groups, particularly in recurrence timing and metastatic sites, and EV‐based therapy was frequently selected after recurrence. Conclusions: Recurrence after adjuvant nivolumab occurred in 28% of patients in real‐world practice. Post‐recurrence management was heterogeneous, and EV‐based therapy was frequently used in this setting. These findings provide hypothesis‐generating real‐world evidence on treatment sequencing after adjuvant nivolumab and require validation in larger cohorts with longer follow‐up.
- 14 September 2026
- Published by Wiley in International Journal of Urology
- Vol. 33 (9) , e70636
Treatment Patterns and Outcomes After Recurrence Following Adjuvant Nivolumab for Urothelial Carcinoma: An AGEHA Real‐World Study
Objectives: To describe post‐recurrence treatment patterns and outcomes after adjuvant nivolumab for urothelial carcinoma in real‐world practice. Methods: We retrospectively analyzed patients with urothelial carcinoma who underwent radical cystectomy or nephroureterectomy followed by adjuvant nivolumab in the multicenter AGEHA database. Among 141 patients, 40 developed recurrence, excluding non‐muscle‐invasive bladder recurrence. First‐line post‐recurrence treatment was categorized as enfortumab vedotin plus pembrolizumab (EVP), enfortumab vedotin (EV), non‐EV regimens, or no systemic therapy. Overall survival (OS) was measured from recurrence and progression‐free survival (PFS) from initiation of first‐line post‐recurrence therapy. Results: Of 141 patients treated with adjuvant nivolumab, 40 (28%) developed recurrence. First‐line post‐recurrence treatment was EVP in 10 patients, EV in 15, non‐EV regimens in 12, and no systemic therapy in 3. Median time from surgery and nivolumab initiation to recurrence was 5.9 and 4.2 months, respectively. Median OS from recurrence was 27.1, 26.0, and 23.4 months in the EVP, EV, and non‐EV groups, respectively, while median PFS from initiation of first‐line post‐recurrence therapy was 12.9, 7.6, and 8.7 months. Baseline characteristics differed across groups, particularly in recurrence timing and metastatic sites, and EV‐based therapy was frequently selected after recurrence. Conclusions: Recurrence after adjuvant nivolumab occurred in 28% of patients in real‐world practice. Post‐recurrence management was heterogeneous, and EV‐based therapy was frequently used in this setting. These findings provide hypothesis‐generating real‐world evidence on treatment sequencing after adjuvant nivolumab and require validation in larger cohorts with longer follow‐up.
- Open Access
- 25 August 2026
- Published by Springer Nature in BMC Cancer
Real-world patterns of first-line treatment selection after the introduction of enfortumab vedotin plus pembrolizumab for advanced urothelial carcinoma
- 25 August 2026
- Published by Springer Nature in BMC Cancer
Open AccessReal-world patterns of first-line treatment selection after the introduction of enfortumab vedotin plus pembrolizumab for advanced urothelial carcinoma
- 15 August 2026
- Published by Wiley in International Journal of Urology
- Vol. 33 (8) , e70598
Visualizing Baseline Eligibility Across Locally Advanced or Metastatic Urothelial Cancer Trials and Real‐World Cohorts
Background: Clinical trials in locally advanced or metastatic urothelial carcinoma (mUC) often enroll younger and fitter patients than those treated in routine practice, limiting applicability to real‐world populations. We developed a simple descriptive metric, the eligibility gap (EG) score, to place trial and real‐world cohorts on a common scale and summarize differences in baseline eligibility profiles. Methods: Pivotal clinical trials were identified through a PubMed search, and three real‐world datasets from Japan, the United States, and Spain were included. The EG score used three consistently reported domains: age, ECOG performance status, and cisplatin eligibility. Each domain was scaled from 0 to 33.3 points and summed to yield a score from 0 to 99.9, with higher scores indicating younger, fitter populations. Robustness was assessed across alternative model specifications, including prespecified weighting schemes, random‐weight simulations, alternative age and ECOG scoring functions, and one‐domain‐out analyses. Results: EG scores were generally higher in cisplatin‐based trials (74.8–90.1) than in immune checkpoint inhibitors (ICI)‐based trials (52.3–81.2) and real‐world cohorts (35.1–45.5), while the cisplatin‐ineligible trial had the lowest score (24.5). Alternative age transformations and a linear ECOG model did not change ranking. In one‐domain‐out analyses, omission of ECOG preserved ranking, whereas omission of age or cisplatin‐fitness produced minor shifts. Across prespecified weighting schemes, rank‐order concordance remained high (Spearman's rho = 0.982–1.000), and 10 000 random‐weight simulations showed a median rho of 0.982. Conclusions: The EG score may provide a simple descriptive summary of eligibility domains across mUC studies, with stable cohort ordering across alternative model specifications.
- 15 August 2026
- Published by Wiley in International Journal of Urology
- Vol. 33 (8) , e70598
Visualizing Baseline Eligibility Across Locally Advanced or Metastatic Urothelial Cancer Trials and Real‐World Cohorts
Background: Clinical trials in locally advanced or metastatic urothelial carcinoma (mUC) often enroll younger and fitter patients than those treated in routine practice, limiting applicability to real‐world populations. We developed a simple descriptive metric, the eligibility gap (EG) score, to place trial and real‐world cohorts on a common scale and summarize differences in baseline eligibility profiles. Methods: Pivotal clinical trials were identified through a PubMed search, and three real‐world datasets from Japan, the United States, and Spain were included. The EG score used three consistently reported domains: age, ECOG performance status, and cisplatin eligibility. Each domain was scaled from 0 to 33.3 points and summed to yield a score from 0 to 99.9, with higher scores indicating younger, fitter populations. Robustness was assessed across alternative model specifications, including prespecified weighting schemes, random‐weight simulations, alternative age and ECOG scoring functions, and one‐domain‐out analyses. Results: EG scores were generally higher in cisplatin‐based trials (74.8–90.1) than in immune checkpoint inhibitors (ICI)‐based trials (52.3–81.2) and real‐world cohorts (35.1–45.5), while the cisplatin‐ineligible trial had the lowest score (24.5). Alternative age transformations and a linear ECOG model did not change ranking. In one‐domain‐out analyses, omission of ECOG preserved ranking, whereas omission of age or cisplatin‐fitness produced minor shifts. Across prespecified weighting schemes, rank‐order concordance remained high (Spearman's rho = 0.982–1.000), and 10 000 random‐weight simulations showed a median rho of 0.982. Conclusions: The EG score may provide a simple descriptive summary of eligibility domains across mUC studies, with stable cohort ordering across alternative model specifications.
- Open Access
- 27 March 2026
- Published by Springer Nature in Cancer Imaging
- Vol. 26 (1)
CT-based renal artery caliber change as a potential imaging marker of treatment response in renal cell carcinoma; an exploratory imaging study
To evaluate whether treatment-induced changes in tumor-bearing renal artery caliber on contrast-enhanced CT are associated with pathological response and p
- 27 March 2026
- Published by Springer Nature in Cancer Imaging
- Vol. 26 (1)
Open AccessCT-based renal artery caliber change as a potential imaging marker of treatment response in renal cell carcinoma; an exploratory imaging study
To evaluate whether treatment-induced changes in tumor-bearing renal artery caliber on contrast-enhanced CT are associated with pathological response and p
- 23 March 2026
- Published by Wiley in International Journal of Urology
- Vol. 33 (3) , e70425
Association of Prophylactic Intravenous Corticosteroid Premedication With Toxicity and Survival in Patients Receiving Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma
Objectives: Enfortumab vedotin (EV) is the standard treatment for locally advanced or metastatic urothelial carcinoma (la/mUC), though skin toxicities are problematic. We evaluated whether prophylactic corticosteroid premedication is associated with reduced toxicity and survival outcomes. Methods: We retrospectively analyzed 157 patients with la/mUC receiving EV monotherapy, stratified by prophylactic intravenous dexamethasone (6.6 mg) premedication (pre‐EV steroid, n = 20) or not (no pre‐EV steroid, n = 137). Endpoints included the incidence of EV‐related adverse events (AEs), objective response rate (ORR), progression‐free survival (PFS), and overall survival (OS). Inverse probability of treatment weighting (IPTW) was used to adjust for baseline imbalances. Results: Corticosteroid premedication was associated with a significantly lower incidence of skin AEs (10% vs. 62.7%, p < 0.001) and a reduced number of cumulative AEs (median 1 vs. 2, p = 0.018). The ORR were comparable. However, patients with steroid premedication showed inferior OS compared to those without (median OS 10.3 vs. 17.4 months, p = 0.008), while PFS showed no significant difference. Multivariable analysis confirmed corticosteroid premedication as an independent predictor of reduced skin AEs (OR 0.08, p = 0.001); however, it was associated with worse OS (HR 1.91, p = 0.048), with no significant impact on PFS. In the IPTW‐adjusted analysis, corticosteroid premedication remained significantly associated with worse OS. Conclusions: Corticosteroid premedication reduces skin toxicities during EV monotherapy, but its impact on survival remains uncertain and requires validation in larger studies.
- 23 March 2026
- Published by Wiley in International Journal of Urology
- Vol. 33 (3) , e70425
Association of Prophylactic Intravenous Corticosteroid Premedication With Toxicity and Survival in Patients Receiving Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma
Objectives: Enfortumab vedotin (EV) is the standard treatment for locally advanced or metastatic urothelial carcinoma (la/mUC), though skin toxicities are problematic. We evaluated whether prophylactic corticosteroid premedication is associated with reduced toxicity and survival outcomes. Methods: We retrospectively analyzed 157 patients with la/mUC receiving EV monotherapy, stratified by prophylactic intravenous dexamethasone (6.6 mg) premedication (pre‐EV steroid, n = 20) or not (no pre‐EV steroid, n = 137). Endpoints included the incidence of EV‐related adverse events (AEs), objective response rate (ORR), progression‐free survival (PFS), and overall survival (OS). Inverse probability of treatment weighting (IPTW) was used to adjust for baseline imbalances. Results: Corticosteroid premedication was associated with a significantly lower incidence of skin AEs (10% vs. 62.7%, p < 0.001) and a reduced number of cumulative AEs (median 1 vs. 2, p = 0.018). The ORR were comparable. However, patients with steroid premedication showed inferior OS compared to those without (median OS 10.3 vs. 17.4 months, p = 0.008), while PFS showed no significant difference. Multivariable analysis confirmed corticosteroid premedication as an independent predictor of reduced skin AEs (OR 0.08, p = 0.001); however, it was associated with worse OS (HR 1.91, p = 0.048), with no significant impact on PFS. In the IPTW‐adjusted analysis, corticosteroid premedication remained significantly associated with worse OS. Conclusions: Corticosteroid premedication reduces skin toxicities during EV monotherapy, but its impact on survival remains uncertain and requires validation in larger studies.
- Open Access
- 8 March 2026
- Published by Wiley in LUTS: Lower Urinary Tract Symptoms
- Vol. 18 (2) , e70056
Overactive Bladder Symptoms as a Predictor of Longitudinal Decline in Grip Strength in Community‐Dwelling Men: A 4‐Year Longitudinal Study
Objectives: Lower urinary tract symptoms (LUTS) are associated with sarcopenia in men. However, it is not clear whether LUTS are related to the decline in physical function. We investigated the longitudinal association between the LUTS severity and the grip strength change in community‐dwelling men. Methods: A 4‐year longitudinal study was conducted using data from 151 men (median age 53 years) enrolled in the Iwaki Health Promotion Project. Grip strength change was calculated as the difference between 2015 and 2019 measurements. LUTS severity was assessed with the International Prostate Symptom Score (IPSS) and the Overactive Bladder Symptom Score (OABSS). Baseline variables included age, Aging Male Symptoms score, serum testosterone, albumin, interleukin‐6, HbA1c, daily exercise, skeletal muscle mass index, and percent body fat. Correlations and multiple regression analyses were performed. Results: The median age and baseline grip strength were 53 years and 41.3 kg, respectively. Grip strength decreased significantly after 4 years, with a median value of −1.1 kg. There was a significant negative correlation between total OABSS, OABSS Q3 (frequency of urinary urgency, r = −0.234, p = 0.003), Q4 (frequency of urge urinary incontinence, r = −0.190, p = 0.020), and grip strength change, whereas the IPSS voiding symptoms domain was not. Multiple regression analysis showed that only the total score of OABSS Q3 and Q4 was significantly correlated with grip strength change (standardized β = −0.930, p = 0.012). Conclusions: The main symptoms of OAB may be indicators of the grip strength decline in men.
- 8 March 2026
- Published by Wiley in LUTS: Lower Urinary Tract Symptoms
- Vol. 18 (2) , e70056
Open AccessOveractive Bladder Symptoms as a Predictor of Longitudinal Decline in Grip Strength in Community‐Dwelling Men: A 4‐Year Longitudinal Study
Objectives: Lower urinary tract symptoms (LUTS) are associated with sarcopenia in men. However, it is not clear whether LUTS are related to the decline in physical function. We investigated the longitudinal association between the LUTS severity and the grip strength change in community‐dwelling men. Methods: A 4‐year longitudinal study was conducted using data from 151 men (median age 53 years) enrolled in the Iwaki Health Promotion Project. Grip strength change was calculated as the difference between 2015 and 2019 measurements. LUTS severity was assessed with the International Prostate Symptom Score (IPSS) and the Overactive Bladder Symptom Score (OABSS). Baseline variables included age, Aging Male Symptoms score, serum testosterone, albumin, interleukin‐6, HbA1c, daily exercise, skeletal muscle mass index, and percent body fat. Correlations and multiple regression analyses were performed. Results: The median age and baseline grip strength were 53 years and 41.3 kg, respectively. Grip strength decreased significantly after 4 years, with a median value of −1.1 kg. There was a significant negative correlation between total OABSS, OABSS Q3 (frequency of urinary urgency, r = −0.234, p = 0.003), Q4 (frequency of urge urinary incontinence, r = −0.190, p = 0.020), and grip strength change, whereas the IPSS voiding symptoms domain was not. Multiple regression analysis showed that only the total score of OABSS Q3 and Q4 was significantly correlated with grip strength change (standardized β = −0.930, p = 0.012). Conclusions: The main symptoms of OAB may be indicators of the grip strength decline in men.
- Open Access
- 28 June 2025
- Published by Wiley in LUTS: Lower Urinary Tract Symptoms
- Vol. 17 (4)
Serum Serotonin Levels as a Potential Risk Factor for Overactive Bladder in a Community‐Dwelling Population: A Four‐Year Longitudinal Study
Purpose: This study aims to investigate the potential influence of serum serotonin (5‐HT) levels on the development of overactive bladder (OAB) in a community‐dwelling population.Methods: A four‐year longitudinal study was conducted involving 615 subjects who participated in the Iwaki Health Promotion Project in Hirosaki, Japan, in both 2015 and 2019. OAB was defined as experiencing urinary urgency at least once a week with an Overactive Bladder Symptom Score (OABSS) of ≥ 3. Baseline data from 2015, including serum 5‐HT levels, other laboratory data, and comorbidity information, were used for the analysis. The association between serum 5‐HT levels and incident OAB in 2019 (OAB‐2019) was examined using multivariate logistic regression analyses.Results: The study included 250 men and 365 women, of whom 74 individuals (29 men and 45 women) met the diagnostic criteria for OAB in 2019. Significant differences were observed between the OAB‐2019 and non‐OAB‐2019 groups, including age, chronic kidney disease, irritable bowel syndrome, hypertension, glycemic status, mental status, and OAB in 2015. Participants in the OAB‐2019 group had significantly lower serum 5‐HT levels compared to the non‐OAB‐2019 group (100 vs. 129 ng/mL, p < 0.001). After adjusting for confounders, multivariable analysis revealed that serum 5‐HT levels < 134 ng/mL (odds ratio: 2.48, 95% confidence interval: 1.39–5.83, p = 0.004), age, mental status, and OAB in 2015 independently served as risk factors for OAB‐2019.Conclusions: Low serum 5‐HT levels may be associated with an increased risk of OAB. Further research is needed to elucidate the underlying mechanisms responsible for this association.
- 28 June 2025
- Published by Wiley in LUTS: Lower Urinary Tract Symptoms
- Vol. 17 (4)
Open AccessSerum Serotonin Levels as a Potential Risk Factor for Overactive Bladder in a Community‐Dwelling Population: A Four‐Year Longitudinal Study
Purpose: This study aims to investigate the potential influence of serum serotonin (5‐HT) levels on the development of overactive bladder (OAB) in a community‐dwelling population.Methods: A four‐year longitudinal study was conducted involving 615 subjects who participated in the Iwaki Health Promotion Project in Hirosaki, Japan, in both 2015 and 2019. OAB was defined as experiencing urinary urgency at least once a week with an Overactive Bladder Symptom Score (OABSS) of ≥ 3. Baseline data from 2015, including serum 5‐HT levels, other laboratory data, and comorbidity information, were used for the analysis. The association between serum 5‐HT levels and incident OAB in 2019 (OAB‐2019) was examined using multivariate logistic regression analyses.Results: The study included 250 men and 365 women, of whom 74 individuals (29 men and 45 women) met the diagnostic criteria for OAB in 2019. Significant differences were observed between the OAB‐2019 and non‐OAB‐2019 groups, including age, chronic kidney disease, irritable bowel syndrome, hypertension, glycemic status, mental status, and OAB in 2015. Participants in the OAB‐2019 group had significantly lower serum 5‐HT levels compared to the non‐OAB‐2019 group (100 vs. 129 ng/mL, p < 0.001). After adjusting for confounders, multivariable analysis revealed that serum 5‐HT levels < 134 ng/mL (odds ratio: 2.48, 95% confidence interval: 1.39–5.83, p = 0.004), age, mental status, and OAB in 2015 independently served as risk factors for OAB‐2019.Conclusions: Low serum 5‐HT levels may be associated with an increased risk of OAB. Further research is needed to elucidate the underlying mechanisms responsible for this association.
- Open Access
- 2 June 2025
- Published by Taylor & Francis in Renal Failure
- Vol. 47 (1) , 2512053
The long-term impact of mild COVID-19 on cardiovascular disease and mortality in patients on hemodialysis: a post-Omicron era retrospective observational study
The long-term cardiovascular (CVD) and mortality risk associated with mild COVID-19 infections in patients on hemodialysis (HD) during the post-Omicron era remains unclear. This study evaluates clinical outcomes in patients on HD following Omicron infection. This retrospective observational study included 462 patients from a single center. All mild COVID-19 cases occurred after January 2022. The first analysis compared patients with prior mild COVID-19 (COVID-19 history [+], n = 63) to those never infected including the observational period (COVID-19 infection [-], n = 286). The second analysis included 392 patients without prior infection, comparing those who acquired mild COVID-19 during follow-up (COVID-19 infection [+]) with those in the COVID-19 infection [-] group. The primary outcome was CVD events. Multivariate analyses assessed COVID-19 infections's impact on clinical outcomes. After 761 days, 100 CVD events including 51 cardiovascular deaths and 58 non-CVD deaths occurred. The CVD risk did not significantly differ between the COVID-19 history (+) and infection (-) groups (Hazard ration [HR]: 0.50, 95% confidence interval [CI]: 0.25-1.01, p = .054) as well as non-CVD mortality. In the second analysis, patients with newly acquired COVID-19 did not exhibit a significantly increased risk of CVD (HR: 0.55, 95% CI: 0.25-1.19, p = .132) or non-CVD mortality. Mild COVID-19 infections does not significantly increase long-term CVD and mortality risk in patients on HD in the post-Omicron era.
- 2 June 2025
- Published by Taylor & Francis in Renal Failure
- Vol. 47 (1) , 2512053
Open AccessThe long-term impact of mild COVID-19 on cardiovascular disease and mortality in patients on hemodialysis: a post-Omicron era retrospective observational study
The long-term cardiovascular (CVD) and mortality risk associated with mild COVID-19 infections in patients on hemodialysis (HD) during the post-Omicron era remains unclear. This study evaluates clinical outcomes in patients on HD following Omicron infection. This retrospective observational study included 462 patients from a single center. All mild COVID-19 cases occurred after January 2022. The first analysis compared patients with prior mild COVID-19 (COVID-19 history [+], n = 63) to those never infected including the observational period (COVID-19 infection [-], n = 286). The second analysis included 392 patients without prior infection, comparing those who acquired mild COVID-19 during follow-up (COVID-19 infection [+]) with those in the COVID-19 infection [-] group. The primary outcome was CVD events. Multivariate analyses assessed COVID-19 infections's impact on clinical outcomes. After 761 days, 100 CVD events including 51 cardiovascular deaths and 58 non-CVD deaths occurred. The CVD risk did not significantly differ between the COVID-19 history (+) and infection (-) groups (Hazard ration [HR]: 0.50, 95% confidence interval [CI]: 0.25-1.01, p = .054) as well as non-CVD mortality. In the second analysis, patients with newly acquired COVID-19 did not exhibit a significantly increased risk of CVD (HR: 0.55, 95% CI: 0.25-1.19, p = .132) or non-CVD mortality. Mild COVID-19 infections does not significantly increase long-term CVD and mortality risk in patients on HD in the post-Omicron era.